Serum FGF21 Levels Are Increased in Obesity and Are Independently Associated With the Metabolic Syndrome in Humans

By Xinmei Zhang, D. C. Yeung, M. Karpíšek, D. Stejskal, Zhiguang Zhou, Feng Liu, R. Wong, W. Chow, A. Tso, K. Lam and 1 more. Diabetes, 2008

925 citations recorded by the source corpus.

Subfields: Epidemiology, Molecular Biology, Nephrology

View Paper: https://www.semanticscholar.org/paper/15fd83bd4034eaa1ca9f781126196f9d74337fbf

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. A. Chait
2. Laura J. den Hartigh

In Molecular Biology

1. E. Maratos-Flier
2. J. Flier
3. A. Chait
4. Laura J. den Hartigh

Citations in the corpus

• Adipose Tissue Distribution, Inflammation and Its Metabolic Consequences, Including Diabetes and Cardiovascular Disease (2020, background): “However, under certain metabolic conditions such as obesity, WAT and BAT may also produce FGF21 (145).”
• Increased Fibroblast Growth Factor 21 in Obesity and Nonalcoholic Fatty Liver Disease (2010, background): “A consistent finding in nearly all of these studies is that circulating FGF21 levels are increased in obesity, insulin resistance, impaired glucose tolerance, and hypertriglyceridemia (9,10,11) and also in individuals with biochemical evidence of liver injury (12).”
• Obesity Is a Fibroblast Growth Factor 21 (FGF21)-Resistant State (2010, background): “Surprisingly, however, FGF21 levels are elevated in obese ob/ob and db/db mice and correlate positively with BMI in humans.”